A pregnancy test is recommended for females of reproductive potential prior to initiating treatment.įemales Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 6 months following the last dose.ĪDVERSE REACTIONS -First-Line Maintenance BRCAm Advanced Ovarian Cancer Discontinue LYNPARZA if pneumonitis is confirmed and treat patient appropriately.Įmbryo-Fetal Toxicity: Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Pneumonitis: Occurred in <1% of patients exposed to LYNPARZA, and some cases were fatal. Discontinue LYNPARZA if MDS/AML is confirmed. If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly until recovery. Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤Grade 1).
0 kommentar(er)
